Abstracts - faqs.org

Abstracts

Health

Search abstracts:
Abstracts » Health

Plasma cell dyscrasias

Article Abstract:

Plasma cell dyscrasias are characterized by a proliferation of a blood cell precursor, usually a plasma cell, and an overproduction of the specific antibody secreted by the cell. Sometimes the excess antibody is deposited in tissues. Multiple myeloma is the most common plasma cell dyscrasia. The blood cell precursor involved is formed during the early stages of hematopoiesis, so patients with MM produce an excess of many different kinds of cells. The proliferation of plasma cells causes bone disease sometimes resembling osteoporosis. Some patients develop kidney disease as a result of antibody and blood cell deposition in the kidney. Waldenstrom's macroglobulinemia is characterized by excess production of IgM antibody. Primary amyloidosis involves the deposition of light-chain antibody fragments. Heavy-chain disease is characterized by excess production of heavy-chain antibody fragments.

Author: Alexanian, Raymond, Barlogie, Bart, Jagannath, Sundar
Publisher: American Medical Association
Publication Name: JAMA, The Journal of the American Medical Association
Subject: Health
ISSN: 0098-7484
Year: 1992
Physiological aspects, Amyloidosis, Macroglobulinemia, Waldenstrom macroglobulinemia, Plasma cell diseases

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Whither interferon for myeloma and other hematologic malignancies?

Article Abstract:

Interferon-alpha may be useful in maintaining remission from multiple myeloma, and it may have a future role in treating other cancers of the blood. Multiple myeloma is a cancer of the blood that causes bone lesions. Better diagnostic tests and more treatments have not improved the survival rate. While the disease cannot be cured, remission can be induced by several treatments. Interferon-alpha has been studied as a potential agent for improving the response of multiple myeloma patients to melphalan-prednisone treatment. Interferon, in combination with melphalan-prednisone, was found to lengthen the period of remission from the disease among some patients. Interferon may also be useful in inducing remission from leukemia.

Author: Alexanian, Raymond, Weber, Donna
Publisher: American College of Physicians
Publication Name: Annals of Internal Medicine
Subject: Health
ISSN: 0003-4819
Year: 1996
Health aspects, Editorial, Chemotherapy, Interferon alpha

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA



Subjects list: Multiple myeloma
Similar abstracts:
  • Abstracts: Renal failure in multiple myeloma: pathogenesis and prognostic implications. Disseminated echovirus infection in a patient with multiple myeloma and a functional defect in complement: treatment with intravenous immunoglobulin
  • Abstracts: Cheiroarthropathy and long term diabetic complications in Nigerians. part 2 Limited joint mobility in children and adolescents with insulin dependent diabetes mellitus
  • Abstracts: Cranial nerve palsy in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma. Two different lymph node metastatic patterns of a prostatic cancer
  • Abstracts: Effects of unrestricted diet on mild infantile diarrhea: a practice-based study
  • Abstracts: Reported practices of pediatric residents in the management of attention-deficit hyperactivity disorder. New York regulation of residents' working conditions: 1 year's experience
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.